A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Dose Range Finding Study of JNJ-39758979 in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy
Overview
- Phase
- Phase 2
- Intervention
- Placebo/JNJ-39758979 (300 mg/d)
- Conditions
- Active Rheumatoid Arthritis; Rheumatoid Arthritis
- Sponsor
- Janssen Research & Development, LLC
- Primary Endpoint
- The primary end point is change from baseline in Disease Activity Score 28 (DAS28) (CRP) at Week 12
- Status
- Withdrawn
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of the study is to assess the efficacy, safety and tolerability of JNJ-39758979 at doses of 10, 30, 100, and 300 mg/day compared with placebo (inactive medical substance) in patients with active rheumatoid arthritis despite concomitant treatment with methotrexate (MTX).
Detailed Description
This is a double-blind (neither physician nor patient knows if the patient is receiving JNJ-39758979 or placebo), multicenter, randomized (patients are assigned to treatment by chance), placebo-controlled, dose range finding study of JNJ-39758979 in patients with stable methotrexate treatment through Week 24. The study will consist of 4 periods: a screening period, a 24-week placebo-controlled period, a 24-week extension period, and a 5-week safety follow-up period. The duration of participation in the study for an individual patient will be up to 59 weeks (including screening). All patients will be randomly assigned in a 1:1:1:1:1 ratio to receive placebo or JNJ-39758979 10 mg, 30 mg, 100 mg, or 300 mg once daily. At Week 24, all patients remaining in the placebo group will start to receive JNJ-39758979 300 mg/day. Safety assessments and evaluations to determine the efficacy of JNJ-39758979 to reduce the signs and symptoms of rheumatoid arthritis will be performed at study visits. The extension and safety follow-up periods of this study will continue through Week 53 in order to assess the safety and for maintenance of efficacy of patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Has a diagnosis of rheumatoid arthritis (RA) for at least 6 months before screening.
- •Positive test for either anti-cyclic citrullinated peptide (anti-CCP) antibody or rheumatoid factor (RF) in serum at screening.
- •Has active RA defined as persistent disease activity with the following criteria: at least 6 swollen and 6 tender joints, and serum CRP ≥ 0.70 mg/dL at screening.
- •Has been treated with and tolerated methotrexate (MTX) treatment at dosages of 10 to 25 mg/week for a minimum of 6 months prior to screening and must be on a stable dose for a minimum of 8 weeks prior to screening
- •Must be post-menopausal or if pre-menopausal, must use an acceptable form of birth control
- •Has completed at least 5 days of daily pain diary in the 10 days prior to randomization.
Exclusion Criteria
- •Has inflammatory diseases other than RA, such as Lupus.
- •Is currently receiving treatment for RA other than methotrexate, NSAIDS, or oral corticosteroids such as prednisone, or pain medicines.
- •Has ever received any biologic agent for a rheumatic indication.
- •Has current signs or symptoms of liver insufficiency or cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, psychiatric, or metabolic disturbances that are severe, progressive, or uncontrolled.
- •Has moderate or severe renal insufficiency
- •Has a recent (within 2 months) serious infection
- •Has had an opportunistic infection.
- •Has had cancer within the past 5 years (except certain skin or cervical conditions)
- •Has abused substances or alcohol within the past 2 years
- •Has active Hepatitis B or C infection
Arms & Interventions
Placebo
Intervention: Placebo/JNJ-39758979 (300 mg/d)
JNJ-39758979 (10 mg/d)
Intervention: JNJ-39758979 (10 mg)
JNJ-39758979 (30 mg/d)
Intervention: JNJ-39758979 (30 mg)
JNJ-39758979 (100 mg/d)
Intervention: JNJ-39758979 (100 mg)
JNJ-39758979 (300 mg/d)
Intervention: JNJ-39758979 (300 mg)
Outcomes
Primary Outcomes
The primary end point is change from baseline in Disease Activity Score 28 (DAS28) (CRP) at Week 12
Time Frame: Baseline, Week 12
Secondary Outcomes
- Percent change from baseline in ESR levels at Week 12 and Week 24(Baseline, Week 12 and Week 24)
- DAS28 (CRP) remission rates at Week 12 and Week 24(Week 12, Week 24)
- Change from baseline in DAS28 (ESR) at Week 12 and Week 24(Baseline, Week 12 and Week 24)
- DAS28 (CRP) response rates at Week 12 and Week 24(Week 12, Week 24)
- DAS28 (ESR) response rates at Week 12 and Week 24(Week 12, Week 24)
- Change from baseline in DAS28 (CRP) at Week 24(Baseline, Week 24)
- American college of rheumatology (ACR) 20/50/70 response rates at Week 12 and Week 24(Week 12, Week 24)
- Hybrid ACR response at Week 12 and Week 24(Week 12, Week 24)
- ACR/European League Against Rheumatism (EULAR) remission rates at Week 12 and Week 24(Week 12, Week 24)
- Change from baseline in Simplified Disease Activity Index (SDAI) at Week 12 and Week 24(Baseline, Week 12, Week 24)
- Change from baseline in Clinical Disease Activity Index (CDAI) at Week 12 and Week 24(Baseline, Week 12, Week 24)
- Health Assessment Questionnaire - Disability Index (HAQ-DI) response at Week 12 and Week 24(Week 12, Week 24)
- Change from baseline in HAQ-DI score at Week 12 and Week 24(Baseline, Week 12 and Week 24)
- Percent change from baseline in ACR components at Week 12 and Week 24(Baseline, Week 12 and Week 24)